Indexé dans
- Ouvrir la porte J
- Genamics JournalSeek
- JournalTOCs
- Répertoire des périodiques d'Ulrich
- RechercheRef
- Université Hamdard
- EBSCO AZ
- OCLC - WorldCat
- Invocation de Proquête
- Publions
- Fondation genevoise pour la formation et la recherche médicales
- Pub européen
- Google Scholar
Liens utiles
Partager cette page
Dépliant de journal
Revues en libre accès
- Agriculture et aquaculture
- Alimentation et nutrition
- Biochimie
- Bioinformatique et biologie des systèmes
- Business & Management
- Chimie
- Génétique et biologie moléculaire
- Immunologie & Microbiologie
- Ingénierie
- La science des matériaux
- Neurosciences & Psychologie
- Science générale
- Sciences cliniques
- Sciences environnementales
- Sciences médicales
- Sciences pharmaceutiques
- Sciences vétérinaires
- Soins infirmiers et soins de santé
Abstrait
Marginal Zone Lymphoma Perge Progredi, Next on the Horizon
Hun Ju Lee, Madhav Desai, Liang Zhang, Qingqing Cai, Dehui Zou and Michael Wang
Marginal Zone Lymphoma (MZL) is a clonal indolent mature B-cell malignancy. MZL accounts for 10% of all Non-Hodgkin Lymphomas (NHL). The common etiologic hallmarks of MZL are chronic antigenic B-cell stimulation, which leads to increased DNA replication errors and genomic instability. Standard therapy for MZL has been watch and wait, cytotoxic chemotherapy, surgery, and/or radiation therapy based on clinical risk factors. However, novel developments of targeted therapies have brought new excitement to MZL therapeutic armamentarium. In this article, we provide an update on the novel diagnostic approaches to MZL as well as innovative molecular targets that will ultimately become the next therapeutic paradigm for patients with MZL.